Previous studies have associated sequence variants in genes coding for the innate immune proteins Toll-like receptor 4 (TLR4), mannose-binding lectin (MBL), and interleukin-1 receptor antagonist (IL-1Ra) to increased risk for either bacterial or viral infection during cancer therapy [7,8,9,10,11,12]. This evidence concerns the gene TLR4 and viral infectious disease.